Clinical trials: Cognitive Investigation
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Cognitive Impairment
Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
Every participant will receive active study drug and one (1 )comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal.
- Trial name
- NCT06382662
- Testing
- metaxalone m640 mg, tizanidine 8mg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Primus Pharmaceuticals
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Depressive Symptoms, Diabetes Mellitus
Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression
This work is supported by the "Kompetenznetz Diabetes mellitus (Competence Network for Diabetes mellitus)" funded by the Federal Ministry of Education and Research (FKZ 01GI0809).
- Trial name
- NCT01009138
- Testing
- Diabetes-Specific CBT (DS-CBT), Standard Diabetes Education
- Where
- Germany
- Volunteers
- 214 people
- Sponsor
- Forschungsinstitut der Diabetes Akademie Mergentheim
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Phobic Disorders
D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
- Trial name
- NCT01102803
- Testing
- Individual Cognitive Behavioral Therapy (CBT), D-Cycloserine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Southern Methodist University
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Addiction
Just-In-Time Adaptive Interventions for Addictive Behaviors
Background: Many smartphone apps intend to help people with addictions. But not enough is known about how they should work. Researchers want to study an app that gives people the advice they need, just when they need it.
- Trial name
- NCT03538652
- Testing
- Formative Interviews (not an intervention), Cognitive-behavioral therapy (CBT), Acceptance and commitment therapy (ACT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cognitive Impairment
A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe
This is a study to determine the effectiveness of the VIZAMYL™ reader training programme in clinical practice in Europe
- Trial name
- NCT04773015
- Where
- 10 sites in Austria, Finland and 3 more
- Volunteers
- 227 people
- Sponsor
- GE Healthcare
Cognitive Decline
An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults
The purpose of this study is to determine whether a 6 month dietary intervention with wild blueberry powder and extract stabilised with L-cysteine and L-glutathione have an effect on cognitive performance in participants aged…
- Trial name
- NCT02446314
- Testing
- Wild Blueberry Powder - 450mg, Wild Blueberry Powder - 900 mg, Wild Blueberry extract 100mg
- Where
- United Kingdom
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Reading
Social Phobia
Social Phobia Intervention Study of Mannheim
Primary objective: The purpose of this study is to examine efficacy and efficiency of a Stepped Care Program (SCP) for patients with Social Phobia in comparison to the standard cognitive therapy for Social Phobia according to…
- Trial name
- NCT00434759
- Testing
- cognitive therapy, stepped care program based on cognitive therapy
- Where
- Germany
- Volunteers
- 89 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Lennox-Gastaut Syndrome
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic…
- Trial name
- NCT01405053
- Testing
- Rufinamide, Any other approved Antiepileptic Drug
- Where
- 47 sites in United States, Canada and 5 more
- Volunteers
- 37 people
- Sponsor
- Eisai Inc.
Alcohol Drinking, Craving
Cognitive Interference Task on Alcohol Craving and Consumption
The purpose of this study is to test a brief task of playing the game Tetris to reduce alcohol cravings and alcohol use. Women who are seen at primary care and recruited through the community will be asked to rate alcohol craving…
- Trial name
- NCT04924283
- Testing
- Tetris and Assessments, Assessment Only
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Healthy
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
- Trial name
- NCT01161472
- Testing
- 4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
- Trial name
- NCT05318937
- Testing
- SAGE-718
- Where
- 38 sites in United States
- Volunteers
- 86 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Sleep
Evaluation of SmartSleep Technology for Improving the Efficiency and Restorative Quality of Sleep in Healthy Adults
This study aims to assess whether slow wave sleep enhancement using SmartSleep technology benefits daytime cognitive performance during periods of chronic sleep restriction.
- Trial name
- NCT03911154
- Testing
- Philips SmartSleep Technology--Continuous Fixed Interval modality, Philips SmartSleep Technology--Block modality, Philips SmartSleep Technology--In-Phase Adjustable modality
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania